The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBatm Advanced Regulatory News (BVC)

Share Price Information for Batm Advanced (BVC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.00
Bid: 17.75
Ask: 18.95
Change: -0.05 (-0.26%)
Spread: 1.20 (6.761%)
Open: 18.30
High: 19.00
Low: 18.00
Prev. Close: 19.05
BVC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

8 Dec 2022 07:00

RNS Number : 9906I
BATM Advanced Communications Ld
08 December 2022
 

LEI: 213800FLQUB9J289RU66

8 December 2022

 

BATM Advanced Communications Limited

("BATM" or "the Group")

 

Trading Update

 

BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, provides the following update on its trading for FY 2022.

 

As stated in its interim results announcement of 24 August 2022, the Group entered the second half with sustained momentum and a significant backlog to be delivered against. BATM made solid progress in both of its divisions as business returns to normality post-pandemic, notwithstanding supply chain issues.

 

Networking and Cyber Division

In the second half of the year, BATM was delighted to announce a multi-year contract for its Edgility solution with UK-based CityFibre in the Networking unit. Work to date reinforces the Group's expectation that deployment and recurring revenues will scale meaningfully in the short term. The Group is also pleased that Edgility is fast being recognised internationally as a breakthrough solution and is winning several awards. Consequently, the interest in Edgility has seen a significant increase and the Group is in advanced discussions with several customers.

 

BATM's Cyber business also made good progress in the second half of the year as the need for cyber security increases daily due to the geo-political situation as well as increased organised criminal activity. As such, the Group's confidence in this unit remains high and it is optimistic of winning a substantial multi-year, multi-million dollar government contract, which would increase the revenues of this division in 2023 and beyond.

 

Bio-Medical Division

In the Diagnostics unit of the Bio-Medical division, the COVID-19 pandemic has demonstrated the capability and value of BATM's diagnostic IP and products. Whilst the transition from the peak pandemic revenues of 2021 introduced an element of volatility to the unit's trading, its performance in 2022 nonetheless indicates its brighter prospects for 2023. In particular, in 2022, the unit's sale of non-COVID diagnostics product saw a dramatic volume increase. From being practically non-existent in 2021, the Group expects to report low double-digit million dollar revenues for sales of its non-COVID diagnostic products this year.

 

Pandemics remain a genuine global concern and COVID remains a very live issue in Asia. The Diagnostic unit was informed that it is due to be awarded a major tender, with a value of $25m, from a customer in Southeast Asia primarily for the delivery of COVID-19 testing kits, and the Group has been awaiting a signed contract. Whilst the Group has had good visibility on this project, given that it is now December, should the contract be received and signed, the revenue would be recognised in 2023 thereby impacting current year expectations for revenue by the corresponding amount and, accordingly, reducing FY 2022 EBITDA.

 

The Eco-Med and Distribution units of the Bio-Medical division have continued to perform in line with management's expectations.

 

BATM is profitable with a very strong balance sheet comprising both cash and investments in financial assets of approximately $40m as well as property and valuable IP. Accordingly, the Board of BATM remains confident in the prospects for the business and continues to explore all options to deliver shareholder value.

 

Enquiries:

 

BATM Advanced Communications

Dr. Zvi Marom, Chief Executive Officer

+972 9866 2525

Moti Nagar, Chief Financial Officer

 

Shore Capital

Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory)

+44 20 7408 4050 

 

Gracechurch Group

Harry Chathli, Claire Norbury

+44 20 4582 3500

 

 

Forward-looking statements  

 

This document contains forward-looking statements. Those statements reflect the current opinions, evaluations and estimations of the Group's management, and are based on the current data regarding the Group's business as is detailed in this document and in the Group's periodical, interim and immediate reports. The Group does not undertake any obligation or make any representation that actual results and events will be in line with those statements, and stresses that they may differ materially from those statements, due to changes in the Group's business, market, competition, demand for the Group's products or services, general economic factors or other factors that can influence the Group's business and results, and due to information and factors that are currently unknown to the Group's management and that, if known, would affect the management's opinions, evaluations or estimations. The Group will report the actual results and events according to its legal, accounting and regulatory obligations, and does not undertake any other obligation to report them or their deviations from the forward-looking statements, or to update any of the forward-looking statements in this document or to report that it is not valid anymore.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFSUEFWEESEIE
Date   Source Headline
14th Apr 20229:30 amRNSAnnual Financial Report
13th Apr 20227:00 amRNSAppointment of Non-Executive Director
4th Apr 20227:00 amRNSTransaction in Own Shares and TVR
18th Mar 20227:00 amRNSStrategic Partnership for Edgility with NEXCOM
17th Mar 202210:30 amRNSResult of General Meeting
10th Mar 202212:30 pmRNSHolding(s) in Company
8th Mar 202211:30 amRNSHolding(s) in Company
28th Feb 20227:00 amRNSFull Year Results
23rd Feb 20227:00 amRNSNotice of General Meeting
21st Feb 20227:00 amRNSStrategic Partnership for Edgility with Advantech
17th Feb 20227:00 amRNSTrading Update and Notice of Results
3rd Feb 202211:23 amRNSClarification on FTSE Nationality Review
3rd Feb 20227:00 amRNSUpdate on FTSE Nationality Review & Share Buyback
31st Jan 20227:00 amRNSUpdate on Ador Diagnostics
17th Jan 20227:00 amRNSUpdate on FTSE Nationality Review
4th Jan 20227:00 amRNSDividend Declaration
4th Jan 20227:00 amRNSTotal Voting Rights
16th Dec 20217:00 amRNSFirst sales of rapid COVID-19 test in Russia
14th Dec 202111:45 amRNSResult of AGM and Dividend Declaration
30th Nov 20217:00 amRNSCOVID-19 tests effective in diagnosing Omicron
25th Nov 20213:00 pmRNSBlock Listing Interim Review
22nd Nov 20213:00 pmRNSNotice of AGM and Dividend Declaration
10th Nov 20217:00 amRNSBATM receives $3.5m cyber security contract
3rd Nov 20217:00 amRNSNew five-year contract for Edgility
1st Nov 20217:00 amRNSBATM receives agri-waste contract in Botswana
7th Oct 20217:00 amRNSStrategic partnership for NFV with AudioCodes
13th Sep 20217:00 amRNSFirst enterprise customer for NFV with $2m order
23rd Aug 20217:00 amRNSInterim Results
12th Aug 20217:00 amRNSNotice of Results
12th Jul 20217:00 amRNSLaunch of Edgility networking NFV-based ecosystem
5th Jul 20217:00 amRNSBATM receives $10m cyber security contract
15th Jun 20217:00 amRNSBATM receives $4.1m cyber security contract
26th May 20217:00 amRNSBlock listing Interim Review
18th May 20217:00 amRNSBATM commences delivery of new COVID-19 tests
19th Apr 202110:25 amRNSAnnual Financial Report
12th Apr 20217:00 amRNSStrategic partnership for NFV
29th Mar 20217:00 amRNSBATM develops molecular diagnostics test for TB
19th Mar 20217:00 amRNSCompletion of Sale of NGSoft
11th Mar 20217:00 amRNSBATM launches no-swab saliva-based COVID-19 test
1st Mar 20217:00 amRNSUpdate on Sale of NGSoft
22nd Feb 20217:00 amRNSFull Year Results
11th Feb 20215:38 pmRNSFTSE Nationality Review
1st Feb 20217:00 amRNSTrading Update and Notice of Results
19th Jan 20217:00 amRNSBATM's NFVTime now available for the public cloud
12th Jan 20217:00 amRNSBATM enters option agreement to sell NGSoft
24th Dec 20207:00 amRNSCOVID-19 test effective in diagnosing new strain
17th Dec 20203:50 pmRNSResult of AGM
15th Dec 20207:00 amRNSUpdate on Ador Diagnostics
7th Dec 20207:00 amRNSDelivery of First Insect Protein Recovery Facility
30th Nov 20203:03 pmRNSTotal Voting Rights and Share Capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.